• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Molecular characterization of rpoB gene mutations in isolates from tuberculosis patients in Cubal, Republic of Angola.安哥拉共和国古巴省结核分枝杆菌分离株 rpoB 基因突变的分子特征。
BMC Infect Dis. 2021 Oct 12;21(1):1056. doi: 10.1186/s12879-021-06763-8.
2
Discordant results between Xpert MTB/RIF assay and Bactec MGIT 960 culture system regarding the detection of rifampin-resistant isolates in Wenzhou, China.Xpert MTB/RIF assay 与 Bactec MGIT 960 培养系统在检测中国温州耐利福平分离株方面的结果不一致。
Microbiol Spectr. 2024 Jun 4;12(6):e0385923. doi: 10.1128/spectrum.03859-23. Epub 2024 May 13.
3
Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis.在一个耐药结核病发病率较低的国家,表型上对利福平敏感的结核分枝杆菌分离株中出现有争议的 rpoB 突变。
BMC Infect Dis. 2019 Jan 3;19(1):3. doi: 10.1186/s12879-018-3638-z.
4
Absence of hybridization with the wild-type and mutant rpoB probes in the Genotype MTBDRplus assay detects 'disputed' rifampicin mutations.在 Genotype MTBDRplus 检测中,与野生型和突变型 rpoB 探针无杂交可检测到“有争议的”利福平突变。
Clin Microbiol Infect. 2018 Jul;24(7):781.e1-781.e3. doi: 10.1016/j.cmi.2017.11.021. Epub 2017 Dec 5.
5
Variable ability of rapid tests to detect Mycobacterium tuberculosis rpoB mutations conferring phenotypically occult rifampicin resistance.快速检测对检测隐匿性耐利福平结核分枝杆菌 rpoB 突变的可变能力。
Sci Rep. 2019 Aug 14;9(1):11826. doi: 10.1038/s41598-019-48401-z.
6
Reevaluating Rifampicin Breakpoint Concentrations for Mycobacterium tuberculosis Isolates with Disputed Mutations and Discordant Susceptibility Phenotypes.重新评估具有争议性突变和不一致药敏表型的结核分枝杆菌分离株的利福平断点浓度。
Microbiol Spectr. 2022 Feb 23;10(1):e0208721. doi: 10.1128/spectrum.02087-21. Epub 2022 Feb 2.
7
Role of Disputed Mutations in the Gene in Interpretation of Automated Liquid MGIT Culture Results for Rifampin Susceptibility Testing of Mycobacterium tuberculosis.在解释自动化液体 MGIT 培养物利福平药敏试验中结核分枝杆菌基因的争议突变的作用。
J Clin Microbiol. 2018 Apr 25;56(5). doi: 10.1128/JCM.01599-17. Print 2018 May.
8
Rifampin-resistance-associated mutations in the rifampin-resistance-determining region of the gene of clinical isolates in Shanghai, PR China.中国上海临床分离株中 基因的利福平耐药决定区的利福平耐药相关突变。
J Med Microbiol. 2021 Mar;70(3). doi: 10.1099/jmm.0.001317. Epub 2021 Jan 28.
9
Profiling and identification of novel rpoB mutations in rifampicin-resistant Mycobacterium tuberculosis clinical isolates from Pakistan.巴基斯坦利福平耐药结核分枝杆菌临床分离株中新的 rpoB 突变的分析和鉴定。
J Infect Chemother. 2021 Nov;27(11):1578-1583. doi: 10.1016/j.jiac.2021.06.020. Epub 2021 Jul 7.
10
Detection of rifampicin resistance of Mycobacterium tuberculosis using multiplex allele specific polymerase chain reaction (MAS-PCR) in Pakistan.利用多重等位基因特异性聚合酶链反应(MAS-PCR)检测巴基斯坦结核分枝杆菌的利福平耐药性。
Infect Genet Evol. 2019 Jul;71:42-46. doi: 10.1016/j.meegid.2019.03.007. Epub 2019 Mar 16.

引用本文的文献

1
Discordance in genotypic and phenotypic drug susceptibility results: time to reconsider critical concentration of rifampicin.基因型和表型药敏结果的不一致:是时候重新考虑利福平的临界浓度了。
Microbiol Spectr. 2025 Mar 4;13(3):e0223624. doi: 10.1128/spectrum.02236-24. Epub 2025 Feb 4.
2
Discordance Between Phenotypic and WGS-Based Drug Susceptibility Testing Results for Some Anti-Tuberculosis Drugs: A Snapshot Study of Paired Isolates with Small Genetic Distance.部分抗结核药物基于表型和全基因组测序的药敏试验结果不一致:对遗传距离小的配对分离株的快照研究
Infect Drug Resist. 2024 Aug 1;17:3289-3307. doi: 10.2147/IDR.S468997. eCollection 2024.
3
Prevalence of Beijing Central Asian/Russian Cluster 94-32 among Multidrug-Resistant in Kazakhstan.哈萨克斯坦耐多药结核病患者中北京中亚/俄罗斯94-32簇的流行情况。
Antibiotics (Basel). 2023 Dec 20;13(1):9. doi: 10.3390/antibiotics13010009.
4
Commensal antimicrobial resistance mediates microbiome resilience to antibiotic disruption.共生抗菌耐药性介导微生物组对抗生素破坏的恢复能力。
Sci Transl Med. 2024 Jan 17;16(730):eadi9711. doi: 10.1126/scitranslmed.adi9711.
5
A precision overview of genomic resistance screening in Ecuadorian isolates of Mycobacterium tuberculosis using web-based bioinformatics tools.利用基于网络的生物信息学工具对厄瓜多尔分枝杆菌分离株进行基因组耐药性筛选的精准概述。
PLoS One. 2023 Dec 5;18(12):e0294670. doi: 10.1371/journal.pone.0294670. eCollection 2023.
6
Phenotype versus genotype discordant rifampicin susceptibility testing in tuberculosis: implications for a diagnostic accuracy.表型与基因型不一致的利福平药敏试验在结核病中的诊断价值:对诊断准确性的影响。
Microbiol Spectr. 2024 Jan 11;12(1):e0163123. doi: 10.1128/spectrum.01631-23. Epub 2023 Nov 20.
7
Isoniazid and Rifampicin Resistance-Conferring Mutations in Isolates from South Africa.来自南非的分离株中赋予异烟肼和利福平耐药性的突变
Pathogens. 2023 Aug 4;12(8):1015. doi: 10.3390/pathogens12081015.
8
Profile and Frequency of Mutations Conferring Drug-Resistant Tuberculosis in the Central, Southeastern and Eastern Ethiopia.埃塞俄比亚中部、东南部和东部地区耐多药结核病相关突变的特征及频率
Infect Drug Resist. 2023 May 12;16:2953-2961. doi: 10.2147/IDR.S408567. eCollection 2023.
9
Performance of Xpert MTB/RIF and sputum microscopy compared to sputum culture for diagnosis of tuberculosis in seven hospitals in Indonesia.在印度尼西亚七家医院中,将Xpert MTB/RIF和痰涂片显微镜检查与痰培养用于结核病诊断的性能比较。
Front Med (Lausanne). 2023 Jan 20;9:909198. doi: 10.3389/fmed.2022.909198. eCollection 2022.

本文引用的文献

1
Low-Level Rifampin Resistance and Mutations in Mycobacterium tuberculosis: an Analysis of Whole-Genome Sequencing and Drug Susceptibility Test Data in New York.结核分枝杆菌低水平利福平耐药与突变:纽约全基因组测序与药物敏感性试验数据的分析。
J Clin Microbiol. 2021 Mar 19;59(4). doi: 10.1128/JCM.01885-20.
2
Mutations Causing Discordant Rifampicin Susceptibility in : Retrospective Analysis of Prevalence, Phenotypic, Genotypic, and Treatment Outcomes.导致利福平药敏结果不一致的突变:患病率、表型、基因型及治疗结果的回顾性分析
Open Forum Infect Dis. 2019 Feb 12;6(4):ofz065. doi: 10.1093/ofid/ofz065. eCollection 2019 Apr.
3
Retrospective Analysis of False-Positive and Disputed Rifampin Resistance Xpert MTB/RIF Assay Results in Clinical Samples from a Referral Hospital in Hunan, China.中国湖南某转诊医院临床样本中利福平耐药 Xpert MTB/RIF 检测假阳性和有争议结果的回顾性分析
J Clin Microbiol. 2019 Mar 28;57(4). doi: 10.1128/JCM.01707-18. Print 2019 Apr.
4
Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis.在一个耐药结核病发病率较低的国家,表型上对利福平敏感的结核分枝杆菌分离株中出现有争议的 rpoB 突变。
BMC Infect Dis. 2019 Jan 3;19(1):3. doi: 10.1186/s12879-018-3638-z.
5
Drug Resistance of Mycobacterium tuberculosis Complex in a Rural Setting, Angola.安哥拉农村地区结核分枝杆菌复合群耐药情况。
Emerg Infect Dis. 2018 Mar;24(3):569-572. doi: 10.3201/eid2403.171562.
6
A standardised method for interpreting the association between mutations and phenotypic drug resistance in .一种标准化方法,用于解释 突变与表型药物耐药性之间的关联。
Eur Respir J. 2017 Dec 28;50(6). doi: 10.1183/13993003.01354-2017. Print 2017 Dec.
7
What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis.什么是耐药性?表型与分子药物耐药性检测对耐多药和广泛耐药结核病治疗的影响。
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01550-17. Print 2018 Feb.
8
Frequency and Type of Disputed Mutations in Isolates from South Korea.韩国分离株中争议性突变的频率和类型
Tuberc Respir Dis (Seoul). 2017 Jul;80(3):270-276. doi: 10.4046/trd.2017.80.3.270. Epub 2017 Jul 3.
9
How should discordance between molecular and growth-based assays for rifampicin resistance be investigated?对于利福平耐药性,应如何研究基于分子检测和基于生长的检测之间的不一致性?
Int J Tuberc Lung Dis. 2017 Jul 1;21(7):721-726. doi: 10.5588/ijtld.17.0140.
10
Prevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosis.通过下一代测序技术检测耐多药结核病异质性耐药的流行率及程度
PLoS One. 2017 May 18;12(5):e0176522. doi: 10.1371/journal.pone.0176522. eCollection 2017.

安哥拉共和国古巴省结核分枝杆菌分离株 rpoB 基因突变的分子特征。

Molecular characterization of rpoB gene mutations in isolates from tuberculosis patients in Cubal, Republic of Angola.

机构信息

Microbiology Department, Vall d'Hebron University Hospital, PROSICS Barcelona, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119 - 129, 08035, Barcelona, Spain.

Infectious Disease Department, Vall d'Hebron University Hospital, PROSICS Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain.

出版信息

BMC Infect Dis. 2021 Oct 12;21(1):1056. doi: 10.1186/s12879-021-06763-8.

DOI:10.1186/s12879-021-06763-8
PMID:34641802
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8507306/
Abstract

BACKGROUND

The importance of Mycobacterium tuberculosis strains with disputed rpoB mutations remains to be defined. This study aimed to assess the frequency and types of rpoB mutations in M. tuberculosis isolates from Cubal, Angola, a country with a high incidence of tuberculosis.

METHODS

All isolates included (n = 308) were analyzed using phenotypic drug susceptibility testing and GenoType MTBDRplus assay. DNA sequencing of the rpoB gene and determination of rifampicin MIC by macrodilution method were additionally performed on isolates yielding discordant results (n = 12) and those in which the mutation detected was not characterized (n = 8).

RESULTS

In total, 85.1% (74/87) of rifampicin-resistant strains had undisputed rpoB mutations -S450L (49), D435V (15), H445D (3), H445Y (2), Q432ins (1), L449M plus S450F (1), S450F (1), S450W (1) and S450Y (1)-; 10.3% (9/87) had disputed rpoB mutations-L430P plus S493L (1), N437del (1), H445L (3), D435Y (2), L452P (2)-, 2.3% (2.3%) showed no rpoB mutations and 2.3% (2/87) showed heteroresistance-D435Y plus L452P and L430P plus S493L-.

CONCLUSION

Disputed rpoB mutations were common, occurring in 10.3% of rifampicin resistant isolates. Current phenotyping techniques may be unable to detect this resistance pattern. To increase their sensitivity, a lower concentration of RIF could be used in these tests or alternatively, rpoB mutations could be screened and characterized in all M. tuberculosis strains.

摘要

背景

具有争议性 rpoB 突变的结核分枝杆菌菌株的重要性仍有待确定。本研究旨在评估安哥拉库巴尔(一个结核病发病率高的国家)分离的结核分枝杆菌菌株中 rpoB 突变的频率和类型。

方法

对所有纳入的分离株(n=308)进行表型药物敏感性试验和 GenoType MTBDRplus 检测。对产生不一致结果的分离株(n=12)和未鉴定突变的分离株(n=8),进行 rpoB 基因的 DNA 测序和利福平 MIC 的微量稀释法测定。

结果

共有 85.1%(74/87)的耐利福平菌株具有无争议的 rpoB 突变-S450L(49)、D435V(15)、H445D(3)、H445Y(2)、Q432ins(1)、L449M 加 S450F(1)、S450F(1)、S450W(1)和 S450Y(1);10.3%(9/87)为有争议的 rpoB 突变-L430P 加 S493L(1)、N437del(1)、H445L(3)、D435Y(2)、L452P(2);2.3%(2.3%)无 rpoB 突变;2.3%(2/87)为异质性耐药-D435Y 加 L452P 和 L430P 加 S493L。

结论

有争议的 rpoB 突变很常见,占耐利福平分离株的 10.3%。目前的表型检测技术可能无法检测到这种耐药模式。为了提高其敏感性,可以在这些检测中使用较低浓度的 RIF,或者可以筛选和鉴定所有结核分枝杆菌菌株的 rpoB 突变。